The final trades of the day with CNBC’s Melissa Lee and the Fast Money traders. The first migrant caravan of the year has set ...
Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...
Short BMY slightly under 59.95, target 53.71, stop loss @ 60.12 Check the time stamp on this data. Updated AI-Generated ...
The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report), with a price ...
This strong market position generates substantial cash flows that support shareholder returns. Turning to the specifics, the ...
**NM signifies a non meaningful value. A dash signifies the data is not available.
PRINCETON, N.J., January 03, 2025 -- ( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 43 rd Annual Healthcare Conference on Monday, ...